HM Payson & Co’s Humacyte HUMA Stock Holding History

HM Payson & Co’s Portfolio HUMA Stock Details HUMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-100	Closed	-$171	–	1021
2025 Q1	$171	Hold	100	–	–	﹤0.01%	1025
2024 Q4	$505	Hold	100	–	–	﹤0.01%	1007
2024 Q3	$544	Hold	100	–	–	﹤0.01%	1064
2024 Q2	$480	Buy	+100	New	+$520	﹤0.01%	971

Other funds holding HUMA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

HM Payson & Co's HUMA Position: Q2 2025 in Review

HM Payson & Co sold out of Humacyte (HUMA) in Q2 2025, closing a stake of 100 shares — an estimated $171 sold.

HM Payson & Co first reported a position in HUMA in Q2 2024 and held it in 4 quarters. The position peaked at $544 in Q3 2024. 156 funds tracked by Wall St. Rank hold HUMA as of Q2 2025.

HM Payson & Co reported no remaining Humacyte position as of Q2 2025 after selling out during the quarter.
HM Payson & Co sold 100 Humacyte shares in Q2 2025, an estimated $171.
HM Payson & Co first reported a position in Humacyte in Q2 2024 and held it in 4 quarters.
HM Payson & Co's Humacyte position peaked at $544 in Q3 2024.
156 funds tracked by Wall St. Rank held Humacyte as of Q2 2025.

Based on HM Payson & Co's 13F filing for Q2 2025, filed 17 Oct 2025.